115437-21-3

Basic information

• Product Name: 7-O-(TRIETHYLSILYL) BACCATIN III
• Synonyms: 7-O-(TRIETHYLSILYL) BACCATIN III;[2aR-(2aα,4β,4aβ,6β,9α,11α,12α,12aα,12bα)]-6,12b-Bis(acetyloxy)-12-(benzoyloxy)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-dodecahydro-9,11-dihydroxy-4a,8,13,13-tetraMethyl-4-[(triethylsilyl)oxy]-7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxet-5-one;7-Triethylsily-Baccatin Ⅲ
• CAS NO: 115437-21-3
• Molecular Formula: C₃₇H₅₂O₁₁Si
• Molecular Weight: 700.88768
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 115437-21-3.mol
• Article Data: 34

Chemical Properties

• Melting Point: 233-235°C
• Boiling Point: 720.2±60.0 °C(Predicted)
• Appearance: /
• Density: 1.24±0.1 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform, Ethyl Acetate, Methanol
• PKA: 12.73±0.70(Predicted)
• CAS DataBase Reference: 7-O-(TRIETHYLSILYL) BACCATIN III(CAS DataBase Reference)
• NIST Chemistry Reference: 7-O-(TRIETHYLSILYL) BACCATIN III(115437-21-3)
• EPA Substance Registry System: 7-O-(TRIETHYLSILYL) BACCATIN III(115437-21-3)

Safety Data

• Hazardous Substances Data: 115437-21-3(Hazardous Substances Data)

Usage

Chemical Properties

Off- White Solid

Uses

Different sources of media describe the Uses of 115437-21-3 differently. You can refer to the following data:
1. A precursor to Paclitaxel
2. A precursor to Paclitaxel.

Upstream product

• 994-30-9 triethylsilyl chloride 
• 27548-93-2 baccatin III 
• 108-24-7 acetic anhydride 
• 115437-18-8 7-triethylsilyl-10-deacetylbaccatin III 
• 32981-86-5 10-deacetylbaccatin III 
• 202341-03-5 (1S,2S,3S,4R,6S,7S,8R,12S)-3,7-Dibenzyloxy-6-(3-butenyl)-4,6-(dicyclohexylsilylenedioxy)-2,12-(isopropylidenedioxy)-1,5,5-trimethyl-9-methylenebicyclo[6.4.0]dodecane 
• 202340-88-3 (1S,2S,3S,6S,7S,8R,12S)-3,7-Dibenzyloxy-6-(cyclohexyldimethylsiloxy)-2,12-(isopropylidenedioxy)-1,5,5-trimethyl-9-methylene-6-(3-oxobutyl)bicyclo[6.4.0]dodecan-4-one 
• 194420-19-4 (1S,2S,3S,4R,6R,7S,8R,12S)-3,7-Dibenzyloxy-4-(tert-butyldimethylsiloxy)-2,12-(isopropylidenedioxy)-6-(p-methoxybenzyloxy)-1,5,5-trimethyl-9-methylenebicyclo[6.4.0]dodecane 
• 222726-71-8 (1S,2S,3S,6S,7S,8R,12S)-3,7-Dibenzyloxy-6-(3-butenyl)-6-(cyclohexylmethylsiloxy)-2,12-(isopropylidenedioxy)-1,5,5-trimethyl-9-methylenebicyclo[6.4.0]dodecan-4-one 
• 194420-17-2 2α,10β-dibenzyloxy-11β-(t-butyldimethylsiloxy)-7β-hydroxy-1α-(p-methoxybenzyloxy)-8β,15,15-trimethyl-4-methylene-trans-bicyclo[6.4.0]dodecan-9-one 
• 202341-14-8 (1S,2S,3S,6S,7S,8R,12S)-3,7-Dibenzyloxy-6-(tert-butyldimethylsiloxy)-2,12-(isopropylidenedioxy)-1,5,5-trimethyl-9-methylene-6-(3-oxobutyl)bicyclo[6.4.0]dodecan-4-one 
• 202340-90-7 (4S,4aS,5S,6S,7R,8R,11S,12S,12aR)-6,12-Dibenzyloxy-11-(cyclohexyldimethylsiloxy)-4,5-(isopropylidenedioxy)-4a,8,13,13-tetramethyl-1-methylenetetradecahydro-7,11-methanobenzocyclodecene-7,8-diol 
• 202340-84-9 (1S,2S,3S,4R,5R,6S,7S,8R,12S)-3,7-Dibenzyloxy-6-(3-butenyl)-4,6-(cyclohexylmethylsilylenedioxy)-2,12-(isopropylidenedioxy)-1,5,5-trimethyl-9-methylenebicyclo[6.4.0]dodecane 
• 202340-86-1 (1S,2S,3R,4R,6S,7S,8R,12S)-3,7-Dibenzyloxy-6-(3-butenyl)-6-(cyclohexylmethylsiloxy)-2,12-(isopropylidenedioxy)-1,5,5-trimethyl-9-methylenebicyclo[6.4.0]dodecan-4-ol 

Downstream Products

• 172481-24-2 7-(triethylsilyl)-13-(trifluoromethanesulfonyl)baccatin III 
• 175441-47-1 C₄₂H₆₆O₁₁Si₃ 
• 189190-72-5 13-β-chloro-7-(triethylsilyl)-A-nor-baccatin III 
• 232920-80-8 C₆₀H₈₉NO₁₅Si₂ 
• 158722-23-7 7-(triethylsilyl)-13-O-[((4S,5R)-2,4-diphenyl-4,5-dihydrooxazol-5-yl)carbonyl]baccatin 
• 819849-41-7 3'-(4-azidophenyl)-2'-tert-butyldimethylsiloxy-3'-dephenyl-7-triethylsiloxypaclitaxel 
• 869735-16-0 C₅₀H₆₃NO₁₃Si 
• 869735-17-1 C₅₂H₆₇NO₁₃Si 
• 485801-36-3 10-acetyl-3'-dephenyl-3'-(2-methylprop-1-enyl)-7-triethylsilyl-2'-triisopropylsilyldocetaxel 
• 289713-99-1 C₆₃H₈₇NO₁₅Si₂ 
• 288390-05-6 C₅₈H₇₉NO₁₆Si₂ 
• 168479-08-1 C₆₀H₈₁NO₁₅Si₂ 

Relevant articles and documents

A chemoselective approach to functionalize the C-10 position of 10- deacetylbaccatin III. Synthesis and biological properties of novel C-10 Taxol analogues

A chemoselective approach to functionalize the C-10 position of 10- deacetyl baccatin III, a key intermediate for the semi-synthesis of paclitaxel, is described. The chemistry provides an easy access to a variety of C-10 hydroxyl derivatives, such as, eth

Total Synthesis of Paclitaxel

The total synthesis of paclitaxel (Taxol) is described. Double Rubottom oxidation of the bis(silyl enol ether) derived from a tricarbocyclic diketone effectively installed a bridgehead olefin and C-5/C-13 hydroxy groups in a one-step operation. The novel Ag-promoted oxetane formation smoothly constructed the tetracyclic framework of paclitaxel.

Novel crystalline forms of anticancer compound CX1409 and preparation method and application of novel crystalline forms of anticancer compound CX1409

The invention relates to the field of compounds, in particular to two novel crystalline forms of an anticancer compound CX1409. A crystalline form A of the anticancer compound CX1409 is determined byusing a powder X-ray diffraction method, wherein characteristic diffraction peaks are shown at 4.3 degree, 8.7 degree, 11.0 degree, 12.5 degree, 13.0 degree, 14.1 degree, 15.4 degree, 17.4 degree, 18.4 degree, 19.6 degree, 20.1 degree, 20.8 degree, 21.7 degree, 27.0 degree, 29.0 degree, 30.6 degree and 31.4 degree in an X-ray powder diffraction spectrum expressed by a diffraction angle of 2 theta+/-0.3 degree; a crystalline form B of the anticancer compound CX1409 is determined by using the powder X-ray diffraction method, wherein characteristic diffraction peaks are shown at 4.9 degree, 5.4degree, 5.8 degree, 6.4 degree, 8.0 degree, 9.4 degree and 12.9 degree in an X-ray powder diffraction spectrum expressed by a diffraction angle of 2 theta +/-0.3 degree. The above two crystalline forms are not reported, outlines of the two crystalline forms are clear, and the two crystalline forms can be perfectly reproduced; besides, the two crystalline forms have the advantages of being good instability of preparation and high in yield and purity, can be applied to anti-tumor drugs, and have wide application prospects.

Antagonizing NOD2 Signaling with Conjugates of Paclitaxel and Muramyl Dipeptide Derivatives Sensitizes Paclitaxel Therapy and Significantly Prevents Tumor Metastasis

A noncleavable paclitaxel (PTX) and N-acetylmuramyl-l-alanyl-d-isoglutamine (MDP) derivative conjugate, 22 (DY-16-43), and its analogues were prepared and characterized as antagonists of NOD2 signaling. This conjugate enhanced the antitumor and antimetastatic efficacy of PTX in Lewis lung carcinoma (LLC) tumor-bearing mice. This work first describes a molecular strategy that enables the sensitization of a chemotherapeutic response via antagonizing NOD2 inflammatory signaling and suggests NOD2 antagonist as potential adjunct in treating non-small-cell lung cancer (NSCLC).